Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model

BACKGROUND Few therapeutic options currently exist to prevent or to mitigate transfusion-associated red blood cell (RBC) alloimmunization. We hypothesized that bortezomib, a proteasome inhibitor currently being utilized for HLA alloantibody and ADAMTS13 autoantibody reduction, may be beneficial in a transfusion setting. Herein, we utilized a reductionist murine model to test our hypothesis that bortezomib would decrease RBC alloimmune responses. STUDY DESIGN AND METHODS Wild-type mice were treated with bortezomib or saline and transfused with murine RBCs expressing the human KEL glycoprotein. Levels of anti-KEL immunoglobulins in transfusion recipients were measured by flow cytometry. The impact of bortezomib treatment on recipient plasma cells (PCs) and other immune cells was also assessed by flow cytometry and immunofluorescence. RESULTS After bortezomib treatment, mice had a 50% reduction in splenic white blood cells and a targeted reduction in marrow PCs. Mice treated with bortezomib before the transfusion of KEL RBCs became alloimmunized in three of three experiments, although their serum anti-KEL IgG levels were 2.6-fold lower than those in untreated mice. Once a primary antibody response was established, bortezomib treatment did not prevent an anamnestic response from occurring. CONCLUSION To the extent that these findings are generalizable to other RBC antigens and to humans, bortezomib monotherapy is unlikely to be of significant clinical benefit in a transfusion setting where complete prevention of alloimmunization is desirable. Given the impact on PCs, however, it remains plausible that bortezomib therapy may be beneficial for RBC alloimmunization prevention or mitigation if used in combination with other immunomodulatory therapies..

Medienart:	Artikel

Erscheinungsjahr:	2017
Erschienen:	2017

Enthalten in:	Zur Gesamtaufnahme - volume:57
Enthalten in:	Transfusion - 57(2017), 1, Seite 82

Sprache:	Englisch

Beteiligte Personen:	Prabitha Natarajan [VerfasserIn] Jingchun Liu [Sonstige Person] Manjula Santhanakrishnan [Sonstige Person] David R Gibb [Sonstige Person] Lewis M Slater [Sonstige Person] Jeanne E Hendrickson [Sonstige Person]

Links:	Volltext search.proquest.com

BKL:	44.86
Themen:	Blood Flow cytometry Prevention Rodents

doi:	10.1111/trf.13864

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC1987961242